Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)
The Librexia-ACS trial will determine the efficacy and safety of milvexian after ACS and will be the first trial to test whether factor XIa inhibition in addition to standard-of-care antiplatelet therapy reduces major adverse cardiovascular events without an increased risk of significant bleeding.
Authors
- S. Claiborne Johnston (ORCID: https://orcid.org/0000-0002-2912-0714)
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- Jay Horrow (ORCID: https://orcid.org/0000-0002-6823-3682)
- Karen S. Pieper (ORCID: https://orcid.org/0000-0003-4190-8341)
- Graeme J. Hankey (ORCID: https://orcid.org/0000-0002-6044-7328)
- Rasha Al Lamee
- Shinya Goto (ORCID: https://orcid.org/0000-0002-6821-1504)
- Kenneth W. Mahaffey (ORCID: https://orcid.org/0000-0002-3791-2148)
- Robert A. Harrington (ORCID: https://orcid.org/0000-0001-5450-8676)
- Danshi Li
- Hsiaowei Deng
- Jeffrey Ian Weitz (ORCID: https://orcid.org/0000-0002-1092-7550)
- C. Michael Gibson
- Maria Cecilia Bahit
- Elliot S. Barnathan
- Shamir R Mehta
- Alexei N. Plotnikov
- Roxana Mehran
Institutions
- Tokai University (JP)
- Beth Israel Deaconess Medical Center (US)
- Mount Sinai Hospital (US)
- Johnson & Johnson (United States) (US)
- Imperial College Healthcare NHS Trust (GB)
- Inserm (FR)
- Bristol-Myers Squibb (Germany) (DE)
- University of California, San Francisco (US)
- Université Paris Cité (FR)
- Cornell University (US)
- Cardiovascular Institute of the South (US)
- Hammersmith Hospital (GB)
- Population Health Research Institute (CA)
- Bristol-Myers Squibb (United States) (US)
- Mount Sinai Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Mount Sinai Hospital (US)
- National University Heart Centre Singapore (SG)
- Instituto de Neurología Cognitiva (AR)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Laboratoire de Recherche Vasculaire Translationnelle (FR)
- Stanford Medicine (US)
- Thrombosis Research Institute (GB)
- Perron Institute for Neurological and Translational Science (AU)
- Hôpital Bichat-Claude-Bernard (FR)
- National Heart Centre Singapore (SG)
- Janssen (United States) (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Alliance nationale pour les sciences de la vie et de la santé (FR)
- Mécanismes moléculaires dans les démences neurodégénératives (FR)
- Hamilton Health Sciences (CA)
- University of Pennsylvania (US)
- McMaster University (CA)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- American Heart Journal
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1016/j.ahj.2025.02.011
- Citations
- 12
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 19.50
Funders
- Bristol-Myers Squibb Foundation
- Bristol-Myers Squibb
- Janssen Research and Development